Uruguay
Tuberculosis profile
Population  2013 3.4 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.04 (0.037–0.042) 1.2 (1.1–1.2)
Mortality (HIV+TB only) 0.02 (0.015–0.026) 0.59 (0.44–0.76)
Prevalence  (includes HIV+TB) 1.2 (0.51–2.1) 35 (15–62)
Incidence  (includes HIV+TB) 1 (0.92–1.1) 30 (27–32)
Incidence (HIV+TB only) 0.13 (0.12–0.14) 3.8 (3.6–4.1)
Case detection, all forms (%) 87 (81–96)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0 (0–0.79) 2.4 (0.06–13)
MDR-TB cases among notified pulmonary
TB cases
0 (0–6) 2 (0–8)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 542   58
Pulmonary, clinically diagnosed 191   9
Extrapulmonary 78   3
       
Total new and relapse 881    
Previously treated, excluding relapses 0    
Total cases notified 881    
Among 881 new and relapse cases:
52 (6%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 371 (68%) 40 (57%) 411
Laboratory-confirmed RR-/MDR-TB cases     4
Patients started on MDR-TB treatment     1
TB/HIV 2013 Number (%)
TB patients with known HIV status 822 (93)
HIV-positive TB patients 120 (15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 51 (43)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 78
Previously treated cases, excluding relapse, registered in 2012 71
HIV-positive TB cases, all types, registered in 2012 50
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) <0.1
Culture (per 5 million population) 1.5
Drug susceptibility testing (per 5 million population) 1.5
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 4.3
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-01 Data: www.who.int/tb/data